ATE366568T1 - Aerosolformulierungen von salmeterol xinafoate - Google Patents

Aerosolformulierungen von salmeterol xinafoate

Info

Publication number: ATE366568T1
Authority: AT; Austria
Prior art keywords: formulations; salmeterol xinafoate; xinafoate; salmeterol; aerosol formulations
Prior art date: 1998-04-24

Application number

AT99920757T

Other languages

English (en)

Inventor

Simon Cooper

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-24

Filing date

1999-04-23

Publication date

2007-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10830947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366568(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-04-23 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE366568T1 publication Critical patent/ATE366568T1/de

Links

GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
239000000443 aerosol Substances 0.000 title abstract 2
229960005018 salmeterol xinafoate Drugs 0.000 title abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
SJJCQDRGABAVBB-UHFFFAOYSA-M 1-hydroxy-2-naphthoate Chemical compound C1=CC=C2C(O)=C(C([O-])=O)C=CC2=C1 SJJCQDRGABAVBB-UHFFFAOYSA-M 0.000 abstract 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
239000003380 propellant Substances 0.000 abstract 1
229960004017 salmeterol Drugs 0.000 abstract 1
229950000339 xinafoate Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99920757T 1998-04-24 1999-04-23 Aerosolformulierungen von salmeterol xinafoate ATE366568T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9808802.4A GB9808802D0 (en)	1998-04-24	1998-04-24	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
ATE366568T1 true ATE366568T1 (de)	2007-08-15

Family

ID=10830947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99920757T ATE366568T1 (de)	1998-04-24	1999-04-23	Aerosolformulierungen von salmeterol xinafoate

Country Status (9)

Country	Link
US (1)	US6613307B1 (de)
EP (1)	EP1073429B1 (de)
JP (1)	JP2002512952A (de)
AT (1)	ATE366568T1 (de)
AU (1)	AU3821399A (de)
DE (1)	DE69936515T2 (de)
ES (1)	ES2289811T3 (de)
GB (1)	GB9808802D0 (de)
WO (1)	WO1999055319A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003514841A (ja) *	1999-11-23	2003-04-22	グラクソグループリミテッド	サルメテロールの医薬製剤
WO2001047493A1 (en) *	1999-12-24	2001-07-05	Glaxo Group Limited	Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
PE20020387A1 (es) *	2000-08-31	2002-06-24	Glaxo Group Ltd	Uso de una combinacion de salmeterol y fluticasona
US6596262B2 (en)	2001-02-15	2003-07-22	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6551578B2 (en) *	2001-02-15	2003-04-22	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6475468B2 (en) *	2001-02-15	2002-11-05	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6485707B2 (en)	2001-02-15	2002-11-26	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6544497B2 (en)	2001-02-15	2003-04-08	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
GB0208742D0 (en) *	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
US7582284B2 (en)	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
US6915966B2 (en) *	2003-01-29	2005-07-12	Specialty Minerals (Michigan) Inc.	Apparatus for the gunning of a refractory material and nozzles for same
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007505136A (ja) *	2003-09-10	2007-03-08	マツプ・フアーマシユーテイカルズ・インコーポレーテツド	ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
RU2006136025A (ru) *	2004-03-12	2008-04-20	Сипла Лимитед (In)	Ингаляционные композиции
CN1957397A (zh) *	2004-03-30	2007-05-02	先锋株式会社	声音识别装置和声音识别方法
US8134010B2 (en)	2004-05-05	2012-03-13	Renopharm Ltd.	Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105065A2 (en)	2004-05-05	2005-11-10	Renopharm Ltd.	Thiazole-based nitric oxide donors for treating inflammatory bowel diseases
US7968575B2 (en)	2004-05-05	2011-06-28	Renopharm Ltd.	Nitric oxide donors and uses thereof
US7498445B2 (en)	2004-05-05	2009-03-03	Renopharm Ltd.	Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1833822A2 (de)	2004-08-16	2007-09-19	Theravance, Inc.	Verbindungen mit beta2 adrenerg-rezeptor agonistischer und muscarin-rezeptor antagonistischer aktivität
GB0418791D0 (en) *	2004-08-23	2004-09-22	Glaxo Group Ltd	Novel process
US7854397B2 (en) *	2005-01-21	2010-12-21	Specialty Minerals (Michigan) Inc.	Long throw shotcrete nozzle
CA2677838C (en)	2007-02-11	2017-08-01	Map Pharmaceuticals, Inc.	Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20090048155A1 (en)	2007-08-15	2009-02-19	Endacea, Inc.	Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
ES2452965T3 (es) *	2007-09-05	2014-04-03	Rigel Pharmaceuticals, Inc.	Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
EP3620154A1 (de)	2009-02-06	2020-03-11	University Of Southern California	Therapeutische zusammensetzungen mit monoterpenen
HUE026414T2 (hu)	2009-07-15	2016-05-30	Theravance Biopharma R&D Ip Llc	Bifenil-vegyület kristályos szabad-bázis formája
US9877967B2 (en)	2010-01-26	2018-01-30	Endacea, Inc.	Methods and pharmaceutical compositions for preventing and treating renal impairment
BR112012022209A2 (pt)	2010-03-03	2017-06-06	Neonc Tech Inc	composições farmacêuticas compreendendo monoterpenos
US20130064870A1 (en) *	2010-05-20	2013-03-14	Sun Pharma Advanced Research Company Limited	Dry powder inhalation composition
CN105078973B (zh)	2010-08-27	2020-10-09	尼昂克技术公司	包含poh衍生物的药物组合物
US20160038600A1 (en)	2012-08-03	2016-02-11	Neonc Technologies Inc.	Pharmaceutical compositions comprising poh derivatives
WO2012032546A2 (en)	2010-09-08	2012-03-15	Cadila Healthcare Limited	Process for the preparation of salmeterol and its intermediates
CN105616391B (zh)	2010-12-17	2021-03-19	尼昂克技术公司	使用异紫苏醇的方法和装置
US9700558B2 (en)	2013-03-15	2017-07-11	Verona Pharma Plc	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
SI3142701T1 (en)	2014-05-12	2018-08-31	Verona Pharma Plc	NEW TREATMENT
WO2015199626A1 (en) *	2014-06-27	2015-12-30	World Medicine İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇	STABLE AEROSOL FORMULATIONS OF β2- ADRENERGIC AGONISTS
EP3872069A1 (de)	2015-02-12	2021-09-01	Neonc Technologies, Inc.	Pharmazeutische zusammensetzungen mit perillylalkoholderivaten
DK3547836T3 (da)	2016-11-30	2024-11-18	Univ Southern California	Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
CN119868317A (zh)	2018-02-08	2025-04-25	南加州大学	穿透血脑屏障的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3706598A (en) *	1970-07-15	1972-12-19	Cpc International Inc	Solid,glass-like starch hydrolysates having high densities
JPH05500229A (ja) *	1991-04-12	1993-01-21	東レ株式会社	固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
DE69205177T2 (de) *	1991-12-12	1996-03-21	Glaxo Group Ltd., Greenford, Middlesex	Pharmazeutische Aerosolformulierung.
US5653962A (en) *	1991-12-12	1997-08-05	Glaxo Group Limited	Aerosol formulations containing P134a and particulate medicaments
US5301664A (en)	1992-03-06	1994-04-12	Sievers Robert E	Methods and apparatus for drug delivery using supercritical solutions
GB9313650D0 (en) *	1993-07-01	1993-08-18	Glaxo Group Ltd	Method and apparatus for the formation of particles
JP3706136B2 (ja) *	1994-09-21	2005-10-12	ネクターセラピューティクス	乾燥粉末薬剤の分散装置及び方法
JP2860951B2 (ja) *	1995-01-12	1999-02-24	株式会社萩原技研	抗菌性ポリマー組成物
US5780014A (en) *	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
MX9707864A (es) *	1995-04-14	1997-11-29	Glaxo Wellcome Inc	Inhalador de dosis medida por salmeterol.
US5977010A (en) *	1995-06-15	1999-11-02	Engelhard Corporation	Shaped hydrogenation catalyst and processes for their preparation and use
GB9606677D0 (en) *	1996-03-29	1996-06-05	Glaxo Wellcome Inc	Process and device

1998
- 1998-04-24 GB GBGB9808802.4A patent/GB9808802D0/en not_active Ceased
1999
- 1999-04-23 ES ES99920757T patent/ES2289811T3/es not_active Expired - Lifetime
- 1999-04-23 US US09/646,872 patent/US6613307B1/en not_active Expired - Fee Related
- 1999-04-23 AU AU38213/99A patent/AU3821399A/en not_active Abandoned
- 1999-04-23 AT AT99920757T patent/ATE366568T1/de not_active IP Right Cessation
- 1999-04-23 DE DE69936515T patent/DE69936515T2/de not_active Revoked
- 1999-04-23 EP EP99920757A patent/EP1073429B1/de not_active Revoked
- 1999-04-23 WO PCT/EP1999/002748 patent/WO1999055319A1/en not_active Ceased
- 1999-04-23 JP JP2000545518A patent/JP2002512952A/ja active Pending

Also Published As

Publication number	Publication date
GB9808802D0 (en)	1998-06-24
US6613307B1 (en)	2003-09-02
EP1073429A1 (de)	2001-02-07
WO1999055319A1 (en)	1999-11-04
ES2289811T3 (es)	2008-02-01
JP2002512952A (ja)	2002-05-08
EP1073429B1 (de)	2007-07-11
AU3821399A (en)	1999-11-16
DE69936515T2 (de)	2007-11-22
DE69936515D1 (de)	2007-08-23

Legal Events

Date	Code	Title	Description
2008-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69936515D1 (de)	2007-08-23	Aerosolformulierungen von salmeterol xinafoate
BR9406995A (pt)	1996-09-10	Carboxilato de I-hidroxi-2-naftaleno (xinafoato) de 4- hidroxi- 1-[[[6-(4-fenilbutoxi)hexil]amino]metil]-1,3- benzenodimetanol (salmeterol) xinafoato de salmeterol e composição farmacêutica
TR200100144T2 (tr)	2001-06-21	Farmasötik aerosol formülasyonu
HUP0401619A3 (en)	2008-03-28	Phenethanolamine derivatives, process for their preparation and pharmaceutical composition containing them
DK0717617T3 (da)	2001-02-05	Mikropartikler indeholdende aktive bestanddele og gas
CL2004000889A1 (es)	2005-03-18	COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
IL203923A (en)	2013-03-24	Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
HUP0300741A3 (en)	2005-12-28	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR020392A1 (es)	2002-05-08	Formulaciones microencapsuladas.
DK0556239T3 (da)	1995-11-06	Aerosol indeholdende medikamenter
MXPA03006538A (es)	2003-09-22	Nuevos derivados de urea, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
DE60301570D1 (de)	2005-10-13	1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
WO2005063194A3 (fr)	2005-10-20	Procede d'innoformulation d'une base galenique biocompatible
AR020391A1 (es)	2002-05-08	Formulaciones microencapsuladas, un procedimiento para su obtencion y empleo de dichas formulaciones.
MXPA03009984A (es)	2004-02-12	PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL.
DK1474491T3 (da)	2006-05-29	Anvendelse af antiadhæsive emballagematerialer til emballering af kemikalier og levnedsmidler
HUP0401369A3 (en)	2006-05-29	Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
WO2002034240A3 (en)	2002-10-10	Delayed and sustained release formulations and method of use thereof
HUP0303195A3 (en)	2007-03-28	O-substituted 6-methyl-tramadol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203212A3 (en)	2005-02-28	Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions
WO2002000191A3 (de)	2003-06-05	Bdellosomen
NO20023249D0 (no)	2002-07-04	Nye substituerte pyrazolo(4,3-e)ediazepiner, farmasöytiske preparater inneholdende disse, anvendelse som medisinske produkterog fremgangsmåter for fremstilling derav
HUP0303804A3 (en)	2005-09-28	Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them
EP1245562A4 (de)	2004-12-15	5-thia-"omega"-(substituiertes phenyl)-prostaglandin e alkohole, verfahren zur herstellung der alkohole und pharmzeutische zusammensetzungen, die diese als aktive inhaltsstoffe enthalten
PL371518A1 (en)	2005-06-27	Method for producing crystals from active ingredients in medicaments, crystals obtained therefrom and the use thereof in pharmaceutical formulations